News Focus
News Focus
icon url

jackrmormon

02/12/11 6:40 PM

#114640 RE: DewDiligence #114634

MNTA's top six FOB targets:

Don't know the patent expiries but have to believe an RA FOB is inevitable. Then Rituxan?
icon url

biomaven0

02/12/11 10:16 PM

#114642 RE: DewDiligence #114634

Interesting that Nexium (number 2 last year) has dropped completely out of the top 10. Insurance company muscle finally having some impact (forcing switches to comparable generics).

Here's data for the top 100 for the last few years:

http://cbc.arizona.edu/njardarson/group/top-pharmaceuticals-poster

Peter